Details of the Drug Combination

General Information of Drug Combination (ID: DC6X1JD)

Drug Combination Name
BRL-15572 Sivelestat
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs BRL-15572   DMM61Y2 Sivelestat   DM6BZCV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 12.56
Bliss Independence Score: 12.56
Loewe Additivity Score: 28.43
LHighest Single Agent (HSA) Score: 28.43

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BRL-15572
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
BRL-15572 Interacts with 9 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [6]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [6]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [6]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [6]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [6]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [6]
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [6]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [6]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTT(s)
Indication(s) of Sivelestat
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 3 [3]
Multiple sclerosis 8A40 Phase 3 [3]
Psoriatic arthritis FA21 Phase 3 [3]
Pyoderma gangrenosum EB21 Phase 3 [4]
Rheumatoid arthritis FA20 Phase 3 [3]
Ulcerative colitis DD71 Phase 3 [3]
Anterior uveitis 9A96 Application submitted [5]
Axial spondyloarthritis FA92.0 Application submitted [3]
Sivelestat Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Pancreatic elastase 1 (CELA1) TT3NKIB CELA1_HUMAN Inhibitor [7]
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 10).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
7 Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
8 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.